

FBXO7 (D8L4E) Rabbit mAb



Orders: 877-616-CELL (2355)

orders@cellsignal.com

Support: 877-678-TECH (8324)

Web: info@cellsignal.com

cellsignal.com

3 Trask Lane | Danvers | Massachusetts | 01923 | USA

For Research Use Only. Not for Use in Diagnostic Procedures.

Applications: W	Reactivity: H M	Sensitivity: Endogenous	MW (kDa): 65-72	Source/Isotype: Rabbit IgG	UniProt ID: #Q9Y3I1	Entrez-Gene Id: 25793
Product Usage Information	2	Application Western Blotting			Dilution 1:1000	
Storage		Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 μg/ml BSA, 50% glycerol and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody.				
Specificity/Sensitivity		FBXO7 (D8L4E) Rabbit mAb recognizes endogenous levels of total FBXO7 protein. FBXO7 (D8L4E) Rabbit mAb detects two bands bands in human cerebellum, consistent with multiple FBXO7 isoforms generated by alternative splicing.				
Source / Purification		Monoclonal antibody is produced by immunizing animals with recombinant protein specific to the N-terminus of human FBXO7 protein.				
Background		F-box only protein 7 (FBXO7) is the substrate recognition component of the SCF (SKP1-CUL1-F-box protein) E3 ubiquitin-protein ligase complex. This complex mediates ubiquitination and degradation of targeted proteins. Several "PARK" chromosomal loci have been associated with monogeneic forms of PD, including PARK15 (1). The associated allele for PARK15 is FBXO7, which encodes the FBXO7 protein. Mutations in FBXO7 cause early-onset autosomal recessive PD, and alterations in FBXO7 normal function, e.g. the protein degradation process, may contribute to PD etiology (2, 3). Additionally, expression of specific FBXO7 isoforms generated by alternative splicing is linked with PD (4).				
Background References		1. Walden, H. and Muqit, M.M. (2017) <i>Biochem J</i> 474, 1439-1451. 2. Burchell, V.S. et al. (2013) <i>Nat Neurosci</i> 16, 1257-65. 3. Vingill, S. et al. (2016) <i>EMBO J</i> 35, 2008-25. 4. Zhao, T. et al. (2011) <i>PLoS One</i> 6, e16983. 5. Zhao, T. et al. (2011) <i>PLoS One</i> 6, e16983.				
Species Reacti	vity	Species reactivity is d	etermined by testin	g in at least one approve	ed application (e.g.,	western blot).
Western Blot Buffer		IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v BSA, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.				
Applications Key		W: Western Blotting				
Cross-Reactivity Key		H: Human M: Mouse				
Trademarks and Patents		Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.				
		All other trademarks more information.	are the property of	their respective owners.	Visit cellsignal.com	/trademarks for
Limited Uses		Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.				
		approved, cleared, or purpose. Customer sl	licensed by the FDA nall not use any Pro	lse Only or a similar labe A or other regulatory for duct for any diagnostic on a statement, Products so	eign or domestic er or therapeutic purp	ntity, for any ose, or otherwise in

any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for

diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.